Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services
TORONTO, ONTARIO--(Marketwired - Oct. 21, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced that it has retained Virtus Advisory Group Inc. ("Virtus"), to develop and implement a strategic investor relations program, which includes enhancing the Company's exposure among industry stakeholders and investors across Canada.
TORONTO, CANADA--(Marketwired - Sept. 17, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced AB569, the Company's drug candidate for treating pulmonary Pseudomonasaeruginosa (P. aeruginosa) infections, has successfully completed pre-clinical in vivo and in vitro validation studies.
Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides
TORONTO, CANADA--(Marketwired - Aug. 5, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, "Brain Tumor Targeting Peptides", further protecting MetaMx™, the Company's peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).